NIH-funded research R01 grant

Finding medicines for understudied human proteins using AI

Official title: AI-powered chemical proteomics for drug discovery targeting orphan proteins

Funded at Northeastern University · NIH-11471580 · Data updated 2026-11-12

Researchers are using AI plus large-scale chemical proteomics to find which small molecules bind and change the activity of understudied human proteins that may be linked to disease.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionNortheastern University
NIH-funded
Lab location1 site (Boston, United States)
Project startAugust 15, 2017
Project endJune 30, 2027
Funding year2025
Award (this year)$381,849
NIH project number7R01GM122845-08
Project IDNIH-11471580 on NIH RePORTER

Who could benefit from this research

Could help

Patients whose conditions are linked to genes or proteins that currently lack drug treatments, or those willing to provide samples or join future translational studies, would be most relevant.

Less likely to help

People seeking an immediate personal clinical benefit or those with conditions already well controlled by existing therapies are unlikely to gain direct benefit from this basic discovery work.

What this research studies

If you have a condition tied to a poorly studied protein, this project aims to find chemicals that stick to those proteins and show whether they turn the protein on or off. The team combines AI models with large genomics and proteomics datasets and high-throughput lab assays to predict protein-chemical interactions and ligand-induced functional effects. Promising predictions are then validated in experiments to confirm binding and functional impact. The goal is to reveal new biological targets and possible starting points for drug development.

Why it matters

Potential benefit: If successful, this work could reveal new drug targets among previously unstudied proteins and speed the discovery of treatments for diseases with unmet needs.

How similar studies have gone: Related AI-driven drug-discovery and chemical proteomics efforts have produced promising leads before, but applying these methods genome-wide to 'dark' proteins is relatively new and experimental.

Where this research is happening

  • Northeastern University
    Boston, United States
    Active

Researchers

  • Principal investigator: Xie, Lei — Northeastern University
  • Study coordinator: Xie, Lei

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.